DarioHealth Corp. (NASDAQ:DRIO – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.71 and traded as low as $0.68. DarioHealth shares last traded at $0.72, with a volume of 140,343 shares.
Analysts Set New Price Targets
Several research firms recently weighed in on DRIO. Stifel Nicolaus dropped their price target on DarioHealth from $3.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. Wall Street Zen cut DarioHealth from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Finally, Litchfield Hills Research initiated coverage on DarioHealth in a report on Monday, May 19th. They issued a “buy” rating and a $3.00 price objective for the company.
Check Out Our Latest Research Report on DarioHealth
DarioHealth Price Performance
DarioHealth (NASDAQ:DRIO – Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.07). The company had revenue of $6.75 million during the quarter, compared to analyst estimates of $7.48 million. DarioHealth had a negative net margin of 159.80% and a negative return on equity of 65.81%. During the same period in the prior year, the firm earned $0.05 earnings per share. As a group, equities research analysts expect that DarioHealth Corp. will post -1.18 earnings per share for the current fiscal year.
Hedge Funds Weigh In On DarioHealth
An institutional investor recently bought a new position in DarioHealth stock. AMH Equity Ltd purchased a new stake in DarioHealth Corp. (NASDAQ:DRIO – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 250,000 shares of the company’s stock, valued at approximately $153,000. AMH Equity Ltd owned about 0.60% of DarioHealth as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 33.39% of the company’s stock.
DarioHealth Company Profile
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Recommended Stories
- Five stocks we like better than DarioHealth
- 5 discounted opportunities for dividend growth investors
- Robinhood Director Sells Millions, But HOOD Stock Eyes Gains
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Super Micro Computer Stock’s Rally Backed by Strong Financials
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.